Vapreotide labeled with Tc-99m for imaging tumors: Preparation and preliminary evaluation

International Journal of Oncology

Volumn 9, Issue 3, 1996, Pages 445-451

  Thakur, M L ^a,d   Kolan, H R ^a   Rifat, S ^a   Li, J ^a   Rux, A ^a   John, E ^a   Halmos, G ^b,c   Schally, A V ^b,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

a somatostatin analog; an octapeptide; preparation and evaluation as a tumor imaging agent; radiolabeled RC 160; receptor binding and stability; somatostatin analog; technetium 99m RC 160; technetium 99m Vapreotide; technetium RC 160

Indexed keywords

MEMBRANE RECEPTOR; PENTETIC ACID; SOMATOSTATIN RECEPTOR; TECHNETIUM 99M; VAPREOTIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN MEMBRANE; BREAST TUMOR; DIAGNOSTIC IMAGING; DRUG RECEPTOR BINDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0029829886     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Srkalovic G, Cai RZ and Schally AV: Evaluation of receptor for somatostatin in various tumors using different analogs. J Clin Endocrinol Metab 70: 661-669, 1990.
2. Brazeau P, Vale W, Burgus R, et al: Hypothalamic polypeptide that inhibits the secretin of immunoreactive pituitary growth hormone. Science 179: 77-79, 1973.
3. Vale W, Brazeau P and Rivier C, et al: Somatostatin. Recent Prog Horm Res 31: 365-397, 1975.
4. Yamada Y, Post SR and Wang K, et al: Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract and kidney. Proc Natl Acad Sci USA 89: 251-255, 1992.
5. Ren-Domiano S, Law SF, Yamada Y, et al: Pharmacological properties of two cloned somatostatin receptors. Mol Pharmacol 42: 28-34, 1992.
6. Raynor K, Murphy WA, Coy DH, et al: Cloned somatostatin receptors: Identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Mol Pharmacol 43: 838-844, 1993.
7. Raynor K, O'Carroll AM, Kong H, et al: Characterization of cloned somatostatin receptors SSTR4 and SSTR5. Mol Pharmacol 44: 385-392, 1993.
8. Reubi JC, Laissue J, Waser B, Horisberger U and Schaer JC: Expression of somatostatin receptors in normal, inflamed and neoplastic human gastrointestinal tissues. Ann NY Acad Sci 733: 123-137, 1994.
9. Bruns C, Weckbecker G, Raulf R, Kaupmann K, Schoeffer P, Hoyer D and Lubbert H: Molecular pharmacology of somatostatin receptor subtypes. Ann NY Acad Sci 733: 138-146, 1994.
10. Lamberts SW, van der Lely AJ, Derherder WW and Hofland LJ: Octreotide. N Engl J Med 334: 246-254, 1996.
11. Lamberts SW, Krenning EP and Reubi JC: The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Rev 12: 450-482, 1991.
12. Reubi JC, Krenning EP, Lamberts SW and Kvols L: Somatostatin receptors in malignant tissues. J Steroid Biochem Mol Biol 37: 1073-1077, 1990.
13. Eden PA and Taylor JE: Somatostatin receptor subtype gene expression in human and rodent tumors. Life Sci 53: 85-90, 1993.
14. Reubi JC, Schaer JC, Waser B and Mengod G: Expression and localization of somatostatin receptor SSTR1, SSTR2 and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 54: 3455-3459, 1994.
15. Bakker WH, Krenning EP, Breeman WA, Kooij PP, Reubi JC, Koper JW, De Jong M, Lameris JS, Visser TJ and Lamberts SW: In vivo use of a radioiodinated somatostatin analogue: Dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man. J Nucl Med 32: 1184-1189, 1991.
16. Becker W, Marienhagen J, Scheubel R, Saptogino A, Bakker WH, Breeman WA and Wolf F: Octreotide scintigraphy localizes somatostatin receptor-positive islet cell carcinoma. Eur J Nucl Med 18: 924-927, 1991.
17. Breeman WA, Hofland LJ, ven der Pluijm M, van Koetsveld PM, DeJong M, Setyono-Han B, Bakker WH, Kwekkeboom DJ, Visser TJ and Lamberts SW: Eur. A new radiolabled somatostatin analogue [111-In-DTPA-D-Phe1] RC-160: Preparation, biological activity, receptor scintigraphy in rats and comparison with [111-In-DTPA-D-Phe1] octreotide. J Nucl Med 21: 328-335, 1994.
18. Scherubl H, Bader M, Fett U, Hamm B, Schmidgt-Gayk H, Koppenhagen K, Dop FJ, Riecken EO and Wiedenmann B: Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. Gastroenterology 105: 1705-1709, 1993.
19. Hammon PJ, Arka A, Peters AM, Bloom SR and Gilbey SG: Localization of metastatic gastrenteropancreatic tumors by somatostatin receptor scintigraphy with [111-In-DTPA-D-Phe1] octreotide. Q J Med 87: 83-88, 1994.
20. Nocaudie-Calzada M, Huglo D, Deveaux M, Camaille B, Proye C and Marchandise X: Iodine-123-Tyr-3-octreotide uptake in pancreatic endocrine tumors and in carcinoids in relation to hormonal inhibition by octreotide. J Nucl Med 35: 57-62, 1994.
21. Van Eyck CH, Bruining HA, Reubi JC, Bakker WH, Oei HY, Krenning EP and Lamberts SW: Use of isotope-labeled somatostatin analogs for visualization of islet cell tumors. World J Surgery 17: 444-447, 1993.
22. Bruns C, Stolz B, Albert R, Marbach P and Pless J: Octreoscan-111 for imaging of a somatostatin receptor-positive islet cell tumor in rat. Horm Metab Res Suppl 27: 5-11, 1993.
23. Joseph K, Stapp J, Reinecke J, Skamel HJ, Hoffken H, Neuhaus C, Lenze H, Trautmann ME and Arnold R: Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors. Horm Metab Res (Suppl) 27: 28-35, 1993.
24. Klapdor R and Montz R: Radioimmunodiagnosis of pancreatic cancer disease. Int J Pancreatol 9: 99-111, 1991.
25. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, DeJong M and Reubi JC: Somatostatin-receptor scintigraphy with [111-In-DTPA-D-Phe1] and [123-I-Tyr3] octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20: 716-773, 1993.
26. Weckbecker G, Raulf F, Stolz B and Bruns C: Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 60: 245-264, 1993.
27. Breeman WA, Hofland LJ, Bakker WH, van der Pluijm M, van Koetsveld PM, DeJong M, Setyono-Han B, Kwekkeboom DJ, Visser TJ and Lamberts SW: Radioiodinated somatostatin analogue RC-160: Preparation, biological activity, in vivo application in rats and comparison with [123-Tyr3] octreotide. Eur J Nucl Med 20: 1089-1094, 1993.
28. Pinski J, Halmos G and Schally AV: Somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice. Cancer Lett 71: 189-196, 1993.
29. Radulovic SS, Milovanovic S, Cai RZ and Schally AV: The binding of bombesin and somatostatin and their analogs to human colon cancers. Proc Soc Exp Biol Med 200: 394-401, 1992.
30. Szepeshazi K, Milovanovic S, Lapis K, Groot K and Schally AV: Growth inhibition of estrogen independent MXT mouse mammary carcinoma in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination. Breast Cancer Res Treat 21: 181-192, 1992.
31. Szende B, Srkalovic G, Schally AV, Lapis K and Groot K: Inhibitory effects of analogs of leuteinizing homrone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Eveans that accompany tumor regression. Cancer 65: 2279-2290, 1990.
32. Lamberts SW, Hofland LJ, van Koetsveld PM, Reubi JC, Bruining A, Bakker WH and Krenning EP: Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: Consequences with regard to diagnosis, localization and therapy. J Clin Endocrinol Metab 71: 566-574, 1990.
33. 1H-NMR and computer modeling coformational analysis. J Biol Chem 269: 12583-12588, 1994.
34. Thakur ML, Halmos G, Jan J, John EK, Li J, Mayo K, Rifat S, Rux A, Varnum JM, Wilder S and Schally AV: Technetium-99m RC-160: A somatostatin analog. J Nucl Med 35: 259P, 1994.
35. Bakker WH, Krenning EP, Breeman WA, Koper JW, Kooij PP, Reubi JC, Klijn JG, Visser TJ, Docter R and Lamberts SW: Receptor scintigraphy with a radioiodinated somatostatin analogue: Radiolabeling, purification, biologic activity and in vivo application in animals. J Nucl Med 31: 1501-1509, 1990.
36. Bakker WH, Albert R, Bruns C, Breeman WA, Hofland LJ, Marbach P, Pless J, Pralet D, Stolz B and Koper JW: [111-In-DTPA-D-Phe1] octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vitro validation. Life Sci 49: 1583-1591, 1991.
37. Raynor K and Reisine T: Analogs of somatostatin selectively label distinct subtypes of somatostatin receptors in rat brain. J Pharmacol Exp Ther 251: 510-517, 1989.
38. Veber PF: In peptide synthesis: Structure and function. In: Proceedings of the Seventh American Peptide Symposium. DH Rich and VJ Gross (eds). Pierce Chemical Co., Rockford, IL., pp685-694, 1981.
39. Zamora PO and Rhodes BA: Imidazoles as well as thiolates in proteins bind Tc-99m. Bioconjugate Chemistry 3: 493-498, 1992.
40. Thakur ML and DeFulvio JD: Technetium-99m labeled monoclonal antibodies for immunoscintigraphy: Simplified preparation and evaluation. J Immunol Methods 137: 217-223, 1991.
41. Babich JW, Graham W and Fischman AJ: Tc-99m labeled hydrazinonicotinamide conjugated chemotactic peptides: Formulation studies to control radiolabeled speciation. J Nucl Med 36: 148P, 1995.
42. Thakur ML: Radiolabeled peptides: Now and the future. Nucl Med Commun 16: 724-732, 1995.
43. Vallabhajosula S, Moyer BR, Lister-James J, McBride BJ, Lipszyc H, Lee H, Bastidas D and Dean RT: Pre-clinical evaluation of Technetium-99m labeled somatostatin receptor binding peptides. J Nucl Med 37: 1016-1022, 1996.